Research Papers:

Quantitative assessment of the association between APC promoter methylation and breast cancer

Keli He, Li Zhang and Xinghua Long _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:37920-37930. https://doi.org/10.18632/oncotarget.9354

Metrics: PDF 1502 views  |   HTML 1940 views  |   ?  


Keli He1,2, Li Zhang1, Xinghua Long1

1Zhongnan Hospital of Wuhan University, Wuhan, 430071, China

2Department of Clinical Laboratory, The First People's Hospital of Changde City, Changde, 415003, China

Correspondence to:

Xinghua Long, email: [email protected]

Keywords: adenomatous polyposis coli, APC, methylation, meta-analysis, breast cancer

Received: January 13, 2016     Accepted: April 26, 2016     Published: May 13, 2016


Adenomatous polyposis coli (APC) is an important tumor suppressor gene in breast cancer. However, there were inconsistent conclusions in the association between APC promoter methylation and breast cancer. Hence, we conducted a meta-analysis to quantitatively assess the clinicopathological significance and diagnosis role of APC methylation in breast cancer. In total, 3172 samples from 29 studies were performed in this study. The odds ratio (OR) of APC methylation was 5.92 (95% CI = 3.16–11.07) in breast cancer cases compared to controls,. The APC promoter methylation was associated with cancer stage (OR = 0.47, 95% CI = 0.28–0.80, P = 0.006), lymph node metastases (OR = 0.55, 95% CI = 0.36–0.84, P = 0.005) and ER status (OR = 1.34, 95% CI = 1.03–1.73, P = 0.003) in breast cancer. Furthermore, the sensitivity and specificity for all included studies were 0.444 (95% CI: 0.321–0.575, P < 0.0001) and 0.976 (95% CI: 0.916–0.993, P < 0.0001), respectively. These results suggested that APC promoter methylation was associated with breast cancer risk, and it could be a valuable biomarker for diagnosis, treatment and prognosis of breast cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9354